Role of prostaglandin E2 in tissue repair and regeneration

Tissue regeneration following injury from disease or medical treatment still represents a challenge in regeneration medicine. Prostaglandin E2 (PGE2), which involves diverse physiological processes via E-type prostanoid (EP) receptor family, favors the regeneration of various organ systems following...

Full description

Saved in:
Bibliographic Details
Published in:Theranostics 2021-01, Vol.11 (18), p.8836-8854
Main Authors: Cheng, Hui, Huang, Haoyan, Guo, Zhikun, Chang, Ying, Li, Zongjin
Format: Article
Language:English
Subjects:
Angiogenesis
Animals
Diabetes
Dinoprostone - metabolism
Dinoprostone - physiology
Fibroblasts
Genotype & phenotype
Humans
Hydrogels
Inflammation
Ischemia
Nonsteroidal anti-inflammatory drugs
Physiology
Regeneration - physiology
Review
Scars
Signal Transduction - drug effects
Skin
Tissue engineering
Wound healing
Wound Healing - physiology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tissue regeneration following injury from disease or medical treatment still represents a challenge in regeneration medicine. Prostaglandin E2 (PGE2), which involves diverse physiological processes via E-type prostanoid (EP) receptor family, favors the regeneration of various organ systems following injury for its capabilities such as activation of endogenous stem cells, immune regulation, and angiogenesis. Understanding how PGE2 modulates tissue regeneration and then exploring how to elevate the regenerative efficiency of PGE2 will provide key insights into the tissue repair and regeneration processes by PGE2. In this review, we summarized the application of PGE2 to guide the regeneration of different tissues, including skin, heart, liver, kidney, intestine, bone, skeletal muscle, and hematopoietic stem cell regeneration. Moreover, we introduced PGE2-based therapeutic strategies to accelerate the recovery of impaired tissue or organs, including 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors boosting endogenous PGE2 levels and biomaterial scaffolds to control PGE2 release.
ISSN:1838-7640
1838-7640
DOI:10.7150/thno.63396